Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $235,594.60 in Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 4,126 shares of the firm’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $57.10, for a total value of $235,594.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Urist also recently made the following trade(s):

• On Monday, September 28th, Marshall Urist sold 4,126 shares of Royalty Pharma stock. The stock was sold at an average price of $57.88, for a total value of $238,812.88.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $56.76 on Thursday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. The business has a 50 day simple moving average of $59.36 and a 200-day simple moving average of $55.19. Royalty Pharma PLC has a 12 month low of $35.23 and a 12 month high of $64.38. The stock has a market capitalization of $32.64 billion, a PE ratio of 39.15, a price-to-earnings-growth ratio of 1.33 and a beta of 0.42.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.05. Royalty Pharma had a net margin of 32.14% and a return on equity of 30.01%. The firm had revenue of $674.14 million for the quarter, compared to analyst estimates of $758.93 million. Equities analysts predict that Royalty Pharma PLC will post 5.32 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Friday, August 14th were given a dividend of $0.2350 per share. This represents a $0.94 annualized dividend and a dividend yield of 1.7%. The ex-dividend date was Friday, August 14th. Royalty Pharma’s payout ratio is presently 64.83%.

Institutional Trading of Royalty Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Capital International Investors grew its holdings in shares of Royalty Pharma by 14.3% during the 4th quarter. Capital International Investors now owns 31,104,309 shares of the biopharmaceutical company’s stock worth $1,201,870,000 after purchasing an additional 3,891,615 shares during the period. Hsbc Holdings PLC raised its holdings in Royalty Pharma by 2,562.2% in the first quarter. Hsbc Holdings PLC now owns 1,544,018 shares of the biopharmaceutical company’s stock valued at $74,000,000 after buying an additional 1,486,020 shares during the period. Renaissance Technologies LLC acquired a new position in Royalty Pharma during the first quarter valued at approximately $37,941,000. Bank of America Corp DE lifted its position in Royalty Pharma by 29.0% during the first quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company’s stock valued at $167,696,000 after buying an additional 786,921 shares in the last quarter. Finally, Carmignac Gestion purchased a new stake in Royalty Pharma during the first quarter worth approximately $30,279,000. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RPRX has been the subject of several recent analyst reports. The Goldman Sachs Group reiterated a “buy” rating and issued a $66.00 price objective on shares of Royalty Pharma in a research note on Thursday, August 6th. Bank of America restated a “buy” rating on shares of Royalty Pharma in a research report on Wednesday, August 5th. TD Cowen lifted their price target on shares of Royalty Pharma from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th. Morgan Stanley boosted their price target on Royalty Pharma from $65.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. upped their price target on Royalty Pharma from $58.00 to $62.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $61.57.

Royalty Pharma Company Profile

Royalty Pharma plc is a biopharmaceutical royalty acquisition company that provides funding to life sciences companies in exchange for rights to future payments associated with approved or development-stage medicines. Its business model gives biotechnology and pharmaceutical companies access to capital while allowing Royalty Pharma to participate in the commercial success of therapies without directly developing or marketing them.

The company invests in royalties and other economic interests tied to a broad range of biopharmaceutical products, including treatments for cancer, rare diseases, immune disorders, diabetes and other chronic conditions.